Gastric cancer (GC) is the third leading cause of cancer death and a major public health care problem worldwide, including in Western populations ([@bib12]). There are only limited diagnostic methods for early detection and no effective screening programs outside some Asian countries ([@bib32]). Consequently, most cases are diagnosed at an advanced stage when the prognosis is dismal ([@bib31]). Thus, there is an urgent search for new, preferentially non-invasive, biomarkers to allow early detection of GC.

High stability and resistance to sample storage handling combined with tissue- and disease-specific disarrangements suggest that small non-coding RNAs (miRNAs), about 22 nucleotides long, present in body fluids are ideally suited for diagnostic applications ([@bib10]). Indeed, preliminary experiments using comprehensive expression profiling showed that serum miRNAs can serve as a potential source for biomarkers for the detection of human malignancies ([@bib9]; [@bib23]). Multiple subsequent clinical studies, including those carried out in patients with GC, suggested that the diagnostic performance of blood miRNAs signatures could outperform most previous serological markers. Nevertheless, despite intensive research with various profiling platforms, there are many unsolved questions addressing the origin and function of circulating miRNAs in cancer ([@bib25]).

Circulating miRNAs are believed to be actively secreted ([@bib18]) or passively released from dead cancer cells and circulate packaged with RNA-binding proteins ([@bib30]), lipoproteins ([@bib33]), and extracellular vesicles ([@bib1]). However, other sources of miRNAs circulating in cancer patients are also plausible, including immune and other blood cells ([@bib26]). Consequently, some studies demonstrated that only a small subset of circulating miRNAs has a tumour-specific origin ([@bib34]). This phenomenon may be even more complex in malignancies of the alimentary system, as experimental studies suggested the importance of hepatic elimination of exogenously administered miRNAs ([@bib3]; [@bib14]). Consequently, the actual source of blood miRNA biomarkers in gastric cancer has not been adequately evaluated and little is known about their distribution, particularly in the Western populations.

To the best of our knowledge, this is the first study of comprehensive miRNome profiling aimed at evaluating the origins of serum microRNA biomarkers for GC. Herein, we first systematically examined miRNA expression profiles of primary gastric cancer and adjacent healthy tissues. Subsequently, serum miRNAs were identified to evaluate whether potential biomarkers found in peripheral blood corresponded to those identified in tumour-draining veins of the portal system.

Materials and methods
=====================

Study design and participants
-----------------------------

The study was planned as a prospective, open label clinical trial. A total of 20 treatment-naive patients with histologically verified advanced non-cardia adenocarcinoma of the stomach scheduled for gastrectomy at the First Department of Surgery Jagiellonian University Medical College from January to December 2015 were recruited. A group of 20 patients subject to upper gastrointestinal endoscopy for complaints related to non-malignant conditions, mostly GERD and cholelithiasis, was selected as controls. Tumour typing and staging were adapted to the recent guidelines ([@bib5]; [@bib11]). The study was approved by the Bioethics Committee of Jagiellonian University and all participants provided their written informed consent upon recruitment.

Sample processing
-----------------

All blood and tissue samples were collected prior to starting any tumour-oriented treatment. Peripheral venous blood (5 ml) was collected into sterile BD Vacutainer tubes under fasting conditions immediately before surgery and from the control subjects. Another 5 ml was drawn intraoperatively from the gastroepiploic vein located in the vicinity of the tumour. After being allowed to clot at room temperature for 60 min, samples were centrifuged at 2000 **g** for 10 min at 4 °C. The serum was removed and stored at −80 °C until analysis.

Pairs of primary tumours and corresponding normal gastric mucosa were sampled from patients' surgical specimens immediately after resection. The fresh specimens were collected into RNase free polypropylene tubes filled with RNAlater stabilisation solution (Qiagen, Valencia, CA, USA) and stored at −80 °C until RNA was extracted. Some portions of the collected specimens were used for routine histopathology to verify adequate cellularity of samples corresponding to tumour tissue and normal gastric mucosa.

RNA extraction
--------------

Total tissue RNA was extracted using miRCURY RNA Isolation Kits (Exiqon, Vedbæk, Denmark) according to the manufacturer's instructions. Prior to RNA extraction from serum samples, tubes were thawed completely on ice and 50 μl of each serum aliquot was spiked-in with 10 fmol synthetic *C. elegans* microRNA (cel-miR-39) (Applied Biosystems, Foster City, CA, USA). Serum RNA extraction for profiling experiments was carried out with TaqMan miRNA ABC Purification Kits Human Panel A and B (Applied Biosystems) containing superparamagnetic Dynabeads covalently bound to 754 anti-miRNA oligonucleotides selected for downstream applications. RNA concentrations were measured with NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA) and overall sample quality was determined by RNA integrity number (RIN) using Agilent Bioanalyser (Agilent Technologies, Palo Alto, CA, USA).

Tissue microRNA expression profiling
------------------------------------

Total RNA (750 ng) isolated from tumour and healthy mucosa samples was labelled with Hy3 and Hy5 fluorescent labels, using the miRCURY LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon) following the manufacturer\'s instructions. Spike-in controls were added to evaluate the labelling reaction, hybridisation, and the performance of the array experiment. The labelled RNA samples were hybridised to the miRCURY LNA microRNA Array 7th Gen (Exiqon) containing capture probes targeting all microRNAs of human origin registered in the miRBASE 19.0. The hybridisation was performed using a Tecan HS4800 hybridisation station (Tecan, Salzburg, Austria) according to the manufacturer's protocol. After hybridisation, the microarray slides were scanned using the Agilent G2565BA Microarray Scanner System (Agilent Technologies) and analysed with the ImaGene 9 software (BioDiscovery, El Segundo, CA, USA). The obtained signals were background corrected and data normalisation was performed with the Lowess (Locally Weighted Scatterplot Smoothing) algorithm. MicroRNAs with intensities above the detection threshold in less than 20% of the samples were removed from the final dataset used for the expression analysis. Microarray data were deposited in a Gene Expression Omnibus database (accession no. GSE93415).

Serum microRNA expression profiling
-----------------------------------

Serum miRNAs were profiled by qRT--PCR using the TaqMan OpenArray assays (Applied Biosystems). Briefly, 0.9--2.7 ng of isolated RNA was reverse transcribed in a 7.5 μl reaction volume using the TaqMan MicroRNA Reverse Transcription Kit and Megaplex RT Primers Human Pools A (v2.1) and B (v3.0) according to the manufacturer's protocol (Applied Biosystems). The resulting cDNA (2.5 μl) was preamplified to increase the quantity of specific cDNA targets with Megaplex PreAmp Primers, Human Pools A (v2.1) and B (v3.0) and the TaqMan PreAmp Master Mix in a final volume of 25 μl (Applied Biosystems). The preamplified product was diluted 40 folds and mixed 1:1v/v with the TaqMan OpenArray Real-Time PCR Master Mix. 5 μl aliquots of the mixture were dispensed on an OpenArray 384-well sample plate. Subsequently, TaqMan OpenArray Human MicroRNA Panels were loaded with the OpenArray AccuFill System and the PCR reactions were carried out with an OpenArray System (Applied Biosystems) following the manufacturer\'s instructions. Values of Ct were processed and exported to DataAssist Software (Applied Biosystems).

Quantitative RT--PCR validation of tissue and serum miRNA profiling experiments
-------------------------------------------------------------------------------

The expression of selected miRNAs was verified by qRT--PCR using TaqMan MicroRNA Assays (Applied Biosystems) according to the manufacturer's instructions. Briefly, total RNA (10 ng) was reverse transcribed in a 15 μl reaction volume using miRNA-specific RT primers and reagents from the TaqMan MicroRNA Reverse Transcription Kit. The resulting cDNA was diluted 1:15 and assayed in 20 μl reaction volumes by qPCR using the corresponding miRNA assay primers and TaqMan Universal PCR Master Mix, No AmpErase UNG. The amplification was performed in 96-well plates with a ViiA 7 real-time PCR instrument (Applied Biosystems) in accordance with the manufacturer's protocols. Three technical replicates were performed for each assay, and the obtained mean Ct values were exported for statistical analysis.

Normalisation for qRT--PCR microRNA expression assays
-----------------------------------------------------

Since there is no consensus about an optimal reference for relative microRNA expression using the qRT--PCR assays, various controls were evaluated separately for serum and tissue samples. Three normalisation strategies for serum were examined with the NormFinder algorithm using most stably expressed miRNAs (endogenous controls), the mean expression of all the genes (global normalisation ([@bib22])), and cel-miR-39 (exogenous control). Reference controls for tissues were evaluated using only the two former methods without exogenous spike-ins. Finally, the expression levels of miRNAs normalised to the most stable references (ΔCt) were calculated by subtracting the reference Ct values from the Ct values of the miRNA of interest ([@bib21]).

Statistical analysis
--------------------

The complete-linkage method and Euclidean distances were used for cluster analysis of microarray data. Comparative expression analysis was done in the software R/Bioconductor using mainly the limma package and moderated t-statistics ([@bib13]). For OpenArray and qRT--PCR experiments, miRNAs with \>10% undetectable expression data were excluded from the calculations; otherwise missing data were replaced by mean values. miRNAs with Ct value 5 amplification cycles lower than negative control and not exceeding 40 cycles were included for further analysis. The Mann--Whitney *U*-test was used to detect differences with regard to ΔCt values. Relative miRNA expression levels between groups were calculated by using the ΔΔCt method ([@bib21]). All raw *P*-values were adjusted for multiple testing by the Benjamini, Krieger, Yekutieli correction ([@bib4]). Statistical analysis was performed using the IBM SPSS Statistics v.24 software package (IBM Corporation, Armonk, NY, USA).

Results
=======

Demographic and clinical characteristics of the study subjects
--------------------------------------------------------------

Clinical and demographic data of the selected population are summarised in [Table 1](#tbl1){ref-type="table"}. No significant difference in age, gender or comorbidities distribution was observed between patients and controls (*P*-values \>0.05). [Figure 1](#fig1){ref-type="fig"} shows a workflow for the subsequent analytical steps.

Identification of reference controls for serum and tissue qRT--PCR normalisation
--------------------------------------------------------------------------------

As expected, tissue and blood samples showed distinct variability of miRNA expression patterns using the NormFinder algorithm. Tissue experiments identified miR-191-5p and miR-298 as the optimum reference controls ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). However, the most stable controls for serum samples included the combination of cel-miR-39 spike-in and miR-191-5p.

Tissue microRNA of primary tumours and healthy gastric mucosa
-------------------------------------------------------------

A total of 975 miRNAs were detected above background levels in at least two tumour samples, including a subset of 108 sequences where the absolute value of the log fold change compared to healthy mucosa was larger than 1 and the corrected *P* value was less than 0.05 (87 upregulated and 21 downregulated miRNAs; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The heat map diagram shows the result of a two-way hierarchical clustering of microRNAs and samples using the complete-linkage method together with the Euclidean distance measure ([Figure 2](#fig2){ref-type="fig"}). [Table 2](#tbl2){ref-type="table"} lists the 10 most significant miRNAs upregulated in tumour tissues and ranked by the relative fold change compared to healthy mucosa. Subsequently, arrays experiments for these 10 molecules were validated using qRT--PCR and expression data were normalised to the average of assays for miR-191-5p and miR-298. The results of qRT--PCR assays showed the same tendency as those of microarray experiments for all miRNAs tested, but fold-change values were generally lower ([Table 2](#tbl2){ref-type="table"}).

Serum miRNAs in gastric cancer and controls
-------------------------------------------

Among the 434 miRNAs initially identified by TaqMan OpenArray assays, 31 sequences showed at least a twofold change in serum of gastric cancer patients compared to controls (all up-regulated; [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). However, the subsequent qRT--PCR validation experiments for these 31 molecules showed that expression of only 20 miRNAs maintained their significance after correction for multiple comparisons with a fold change ranging from 4 (miR-30c) to 230 (miR-518f) ([Table 3](#tbl3){ref-type="table"}). There were no significant differences in these miRNAs in relation to the primary tumour (T2--T3 *vs* T4) or distant metastases (M0 *vs* M1).

Portal and peripheral blood miRNAs
----------------------------------

Paired serum samples obtained from peripheral and gastroepiploic veins were evaluated to determine whether miRNA biomarkers found in peripheral blood corresponded to those identified in tumour-draining veins of the portal system. Eight of the evaluated miRNAs showed significantly increased levels in the peripheral circulation by TaqMan OpenArray cards and these sequences were subsequently validated with qRT--PCR assays ([Table 4](#tbl4){ref-type="table"}). Moreover, the up-regulated group included miR-331 and miR-21, which were earlier identified as potential biomarkers of gastric cancer comparing miRNA expression in peripheral blood of patients and controls ([Table 3](#tbl3){ref-type="table"}).

Correlation of tissue and blood miRNAs
--------------------------------------

To correlate profiles of tissue and circulating miRNAs, we compared expression levels of primary tumours and healthy gastric mucosa with peripheral blood of patients and healthy controls. Among 20 miRNAs upregulated in the peripheral blood of cancer patients, only seven ([Figure 3](#fig3){ref-type="fig"}) demonstrated higher levels in tumours compared to adjacent normal mucosa (miR-130a, miR-331, miR-19a, miR-223, miR-106a, miR-21, and miR-374).

Discussion
==========

Circulating miRNAs found in all body fluids may potentially serve as clinically relevant biomarkers of human malignancies. Herein, it was found that serum levels of miRNAs detected in tumour-draining veins of the portal system poorly corresponded to molecules abundantly expressed by primary tumours of gastric cancer. Moreover, some potential biomarkers were significantly up-regulated in peripheral blood suggesting that these miRNAs are not released from the tumour.

The remarkable stability of miRNAs under various environmental conditions initiated extensive research to validate serum and plasma profiling in search of putative cancer biomarkers ([@bib10]). Such attempts were undertaken also for gastric cancer, suggesting that assays using blood miRNAs could markedly outperform currently available solutions ([@bib38]; [@bib37]). However, the results of previous studies are highly inconsistent for most malignancies and question any physiological role of miRNAs. One of the potential explanations for this discrepancy is the suspicion that potential biomarker candidates in fact originate from other sources than the primary tumour, such as normal tissues of other organs or blood cells ([@bib24]; [@bib27]).

Comprehensive expression profiling of miRNAs in the current study based on a well-defined population of Western patients with gastric cancer provides a unique opportunity to study the origins of potential serum biomarkers. Initially, 20 of 434 miRNA sequences identified in peripheral blood serum were significantly up-regulated in cancer patients. However, only seven of them showed higher levels in primary tumours compared to adjacent normal mucosa. Moreover, two potential biomarkers (miR-331 and miR-21) demonstrated higher expression in peripheral blood than in the tumour-draining vein. Altogether, our results strongly suggest non-tumour origins for the majority of circulating miRNA biomarkers. To our knowledge no previous study has evaluated the correlation between potential miRNA biomarkers of gastric cancer in tumour tissue with reference to portal and peripheral blood.

Early experiments have demonstrated that miRNAs originating from human cancer xenografts enter the circulation and can be readily measured in plasma ([@bib23]). However, in the mice model of gastric cancer, the comparison of tissue and serum samples showed that only some miRNAs differentiating cancer and normal tissues were overexpressed in serum ([@bib28]). Human observations supporting such animal data are scarce as even though some human studies correlated tissue and serum/plasma levels of miRNAs, such assays were often carried out in separate sets of patients and only a few reported results on a within-patient basis. One such study examined levels of miRNAs identified as significantly elevated (miR-223 and miR-21) and decreased (miR-218) in plasma of gastric cancer compared to healthy controls in 8 pairs of primary tumours and adjacent normal tissue ([@bib19]). The expression of miR-223 and miR-21 was higher in seven and eight, respectively, of eight cancer tissues than in controls, whereas miR-218 was lower in seven of eight patients. A similar experimental procedure was carried out in four pairs of primary tumours and healthy adjacent tissues with miR-378 identified as significantly elevated (threefold) in serum of cancer patients compared to controls ([@bib20]). However, contrary to the expectations, tissue levels of miR-378 were significantly lower in primary tumours than in healthy tissues. Another study examined miR-451 and miR-486 identified as diagnostic biomarkers for gastric cancer based on pre- and post-operative paired plasma samples ([@bib17]). Despite high diagnostic sensitivity and specificity of 96% and 100%, respectively, for detecting GC compared to healthy controls, the miR-451 expression was found to be significantly lower in primary tumours than in surrounding normal tissues, while miR-486 expression was comparable. Altogether, these results imply that the circulating pool of miRNA biomarkers of gastric cancer originates not only from the primary tumour but also may reflect a yet unknown biological phenomenon elicited by the presence of cancer.

It is still poorly understood why miRNAs with a relatively low expression in primary tumours are abundantly expressed in plasma or serum of GC patients compared to healthy controls. There are at least two likely explanations. First, previous observations in some other malignancies, such as breast cancer, showed that only a few differentially expressed miRNAs were common to tumours and serum and the potential biomarkers were selectively released to circulation ([@bib6]; [@bib39]). Second, circulating miRNAs might also originate from non-tumour tissues. Such a mechanism could explain our observations related to miR-21 and miR-331 that achieved markedly higher expression levels in peripheral blood than in the vein draining the primary tumour. The plausibility of this phenomenon is further substantiated by experiments carried out with animal models and clinical observations of breast cancer where some of extracellular miRNA was derived from normal epithelial cells ([@bib24]).

Aberrant expression of miR-21 was identified in tissue and blood of various malignancies, suggesting its potential role as a diagnostic and prognostic biomarker ([@bib35]). This was likely related to the oncogenic activity of miR-21 that can stimulate proliferation, migration, and invasion of cancer cells, including gastric cancer ([@bib29]). In the latter case, the molecule has been demonstrated to modulate the expression of multiple genes, such as epidermal growth factor receptor (EGFR), phosphatase and tensin homologue (PTEN), programmed cell death 4 (PDCD4), Fas ligand (FASLG), and reversion-inducing cysteine-rich protein with kazal motifs (RECK). Contrary to miR-21, miR-331 has been much less extensively studied. Therefore, the actual function of the molecule is somehow unclear as previous experiments suggested its ability to promote proliferation and metastasis ([@bib7]), as well as inhibit cell growth and promote apoptosis ([@bib36]). Nevertheless, it was reported as a circulating biomarker for several tumours, including hepatocellular carcinoma ([@bib8]), laryngeal cancer ([@bib2]), and colorectal adenomas ([@bib15]). In the current study, the exact significance of increased expression levels for miR-21 and miR-331 found in peripheral blood compared to tumour-draining veins is unclear, but suggests that some diagnostic miRNA biomarkers may actually originate from tissues distant to the primary tumour.

Despite a moderate sample size, our results provide an important framework for further studies focused on blood miRNome of gastrointestinal malignancies to elucidate the origins of cancer-associated biomarker miRNAs. However, some important limitations should be considered. First, an appropriate normalisation strategy is a key step for the accurate relative quantification of miRNA expression levels with qRT--PCR. However, there are no generally accepted internal controls for plasma/serum miRNA measurement to date, and the discussion over selection of the most appropriate reference genes in miRNA profiling studies is ongoing ([@bib22]; [@bib16]). To minimise the potential bias of using inadequate controls we have tested all currently recommended normalisation strategies (endogenous and exogenous controls, global normalisation) and accordingly selected the most suitable approach. Second, we have evaluated only serum miRNome without molecules present in plasma or bound to membrane vesicles. Although some minor differences in plasma and serum pools of miRNAs have been demonstrated, they seem unlikely to affect identification of potential biomarkers. Moreover, the selection of serum could be more relevant for clinical applications. Third, no laser microdissection was used to selectively isolate cancer cells for subsequent miRNA profiling, but microscopic validation was used to confirm representative components of primary tumours. Although the former method is more specific for isolation of cancer cells, the latter more likely reflects the heterogeneity of cellular components of the primary tumours and their miRNA contents. Finally, differences in miRNA expression patents within the primary tumour that were not evaluated in the present study could potentially affect our results.

In summary, we conducted a comprehensive miRNA profiling of primary gastric cancer and adjacent healthy tissues combined with serum samples of portal and peripheral blood to investigate the potential diagnostic biomarkers. Poor correlations between differentially expressed miRNAs in tissues and blood suggest that a marked proportion of potential biomarker molecules originate from tissues other than the primary tumour, reflecting a yet unknown biological phenomenon. This has important implications for further studies to elucidate the role and origins of circulating cancer-associated miRNAs, and should be validated by other research groups.
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![**Workflow showing the analytical strategy for the identification of microRNAs.** ](bjc2017190f1){#fig1}

![**Heat map and unsupervised hierarchical clustering based on the 50 most differentially expressed miRNAs between primary tumours and adjacent healthy mucosa.** The miRNA overexpression is in green, and lower miRNA expression is in red. Numbers correspond to paired samples from individual patients with 'H' denoting healthy mucosa.](bjc2017190f2){#fig2}

![**Box plots of relative miRNA expression levels in tissues and peripheral blood.** The statistical significance of differences was calculated using the Mann--Whitney *U*-test (\**P*\<0.05). The line inside the boxes indicates median values with the upper and lower limits corresponding to the 75th and 25th percentiles, respectively. The upper and lower horizontal whiskers denote the 95th and 5th percentiles respectively.](bjc2017190f3){#fig3}

###### Clinicopathological details of patients

                                             **Gastric cancer (*****n*****=20)**   **Controls (*****n*****=20)**
  ----------------------------------------- ------------------------------------- -------------------------------
  Age, median (range)                                    64 (34--81)                        62 (32--78)
  Female/male, *n* (%)                                 9 (45)/11 (55)                     9 (45)/11 (55)
  Comorbidities, *n* (%)                                                                          
   Circulatory[a](#t1-fn1){ref-type="fn"}                  14 (70)                            12 (60)
   Pulmonary[b](#t1-fn2){ref-type="fn"}                    2 (10)                             2 (10)
   Diabetes mellitus                                       4 (20)                             5 (25)
  Location, *n* (%)                                                                               
   Upper third                                             2 (10)                                 
   Middle third                                            8 (40)                                 
   Distal third                                            5 (25)                                 
   Whole stomach                                           5 (25)                                 
  Differentiation                                                                                 
   Well                                                    2 (10)                                 
   Moderately                                              3 (15)                                 
   Poor                                                    15 (75)                                
  Lauren classification                                                                           
   Intestinal                                              4 (20)                                 
   Diffuse                                                 9 (45)                                 
   Mixed                                                   7 (35)                                 
  Stage                                                                                           
   II                                                      2 (10)                                 
   III                                                     13 (65)                                
   IV                                                      5 (25)                                 

Ischemic heart disease, arrhythmia, previous myocardial infarction, coronary artery disease.

Asthma, chronic obstructive pulmonary disease.

###### Ten most upregulated miRNAs in gastric cancer tissue when compared with normal gastric mucosa

  **Annotation**   **microRNA array**   **RT--PCR validation**         
  ---------------- -------------------- ------------------------ ----- -------
  miR-199a-3p      4.6                  0.002                    3.6   0.001
  miR-199a-5p      3.7                  0.001                    2.7   0.002
  miR-223-3p       3.7                  0.002                    3.1   0.005
  miR-125b-5p      3.7                  0.002                    2.6   0.004
  miR-27a-3p       3.5                  0.002                    2.8   0.001
  miR-196a-5p      3.5                  0.001                    2.7   0.001
  miR-23b-3p       3.5                  0.002                    3.1   0.002
  miR-21-5p        3.2                  0.001                    2.6   0.004
  miR-23a-3p       3.2                  0.001                    2.6   0.003
  miR-20a-5p       3.0                  0.001                    2.0   0.001

Abbreviations: miRNA=microRNA; RT--PCR=reverse transcriptase PCR.

Benjamini, Krieger, and Yekutieli correction for multiple testing.

###### Upregulated serum miRNAs evaluated by qRT--PCR in the peripheral blood of patients with gastric cancer when compared with healthy controls

  **miRNAs**   **ΔCt**~**healthy**~   **ΔCt**~**cancer**~   **ΔΔCt**   **2**^**--ΔΔCt**^   **Corrected** ***P***[a](#t3-fn5){ref-type="fn"}
  ------------ ---------------------- --------------------- ---------- ------------------- --------------------------------------------------
  miR-518f     −4.50±10.78            −12.35±1.99           −7.85      230.67              0.017
  miR-130a     10.96±3.48             6.62±3.42             −4.34      20.22               0.017
  miR-212      8.81±2.36              4.58±2.65             −4.22      18.70               0.007
  miR-220      7.85±2.51              3.85±2.81             −4.00      15.98               0.017
  miR-433      9.03±1.67              5.19±3.15             −3.84      14.29               0.025
  miR-518d     8.77±3.76              5.43±3.24             −3.35      10.18               0.037
  miR-331      6.54±2.61              3.31±3.34             −3.23      9.40                0.039
  miR-19a      8.39±4.07              5.18±3.55             −3.21      9.23                0.042
  miR-365      10.66±3.22             7.62±3.12             −3.04      8.25                0.037
  miR-374      8.48±3.24              5.55±2.94             −2.93      7.62                0.037
  miR-296      7.74±4.29              4.86±3.14             −2.88      7.37                0.039
  miR-323-3p   9.21±1.60              6.59±2.94             −2.63      6.18                0.046
  miR-21       4.05±2.33              1.73±2.45             −2.33      5.02                0.017
  miR-146b     6.95±2.34              4.64±2.21             −2.31      4.97                0.037
  miR-146a     5.99±2.19              3.68±2.65             −2.31      4.96                0.025
  miR-106a     4.30±2.77              2.10±2.51             −2.19      4.57                0.025
  miR-223      −2.65±2.32             −4.78±2.57            −2.12      4.35                0.025
  miR-19b      2.45±2.23              0.36±2.63             −2.09      4.26                0.025
  miR-451      0.68±2.31              −1.41±2.84            −2.08      4.23                0.037
  miR-30c      4.95±3.3               2.90±2.65             −2.05      4.14                0.037

Abbreviations: miRNA=microRNA; qRT--PCR=quantitative reverse transcriptase PCR.

Values are expressed as means±s.d.

ΔC~t~=C~t\ sample~−C~t\ average\ expression\ of\ *cel-*miR-39\ and\ miR-191-5p.~

ΔΔC~t~=ΔC~t\ cancer~−ΔC~t\ healthy.~

Benjamini, Krieger, and Yekutieli correction for multiple testing.

###### Dysregulated miRNAs in peripheral circulation when compared with portal blood by qRT--PCR

  **miRNAs**   **ΔCt**~**peripheraL**~   **ΔCt**~**portal**~   **ΔΔCt**   **2**^**--ΔΔCt**^   ***P-*****value**   **Corrected** ***P-*****value**[a](#t4-fn5){ref-type="fn"}
  ------------ ------------------------- --------------------- ---------- ------------------- ------------------- ------------------------------------------------------------
  miR-21       1.73±2.45                 5.28±3.09             −3.55      11.71               0.001               0.004
  miR-16       0.36±3.42                 3.81±3.91             −3.45      10.94               0.045               0.045
  miR-99a      1.13±2.37                 4.29±1.18             −3.15      8.88                0.016               0.032
  miR-95       6.96±2.71                 10.04±2.21            −3.08      8.46                0.012               0.032
  miR-532      5.42±1.22                 8.48±1.21             −3.06      8.34                0.029               0.033
  miR-891a     2.77±1.79                 5.80±1.66             −3.03      8.19                0.001               0.004
  miR-331      3.31±3.34                 5.40±2.37             −2.09      4.26                0.028               0.033
  miR-92a      0.19±1.89                 2.26±2.02             −2.07      4.20                0.027               0.033

Abbreviations: miRNA=microRNA; qRT--PCR=quantitative reverse transcriptase PCR.

Values are expressed as means±s.d.

ΔC~t~=C~t\ sample~−C~t\ average\ expression\ of\ *cel-*miR-39\ and\ miR-191-5p~

ΔΔC~t~=ΔC~t\ peripheral~−ΔC~t\ portal~.

Benjamini, Krieger, and Yekutieli correction for multiple testing.
